PDT Partners LLC Buys 3,057 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

PDT Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 101.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,058 shares of the biopharmaceutical company's stock after purchasing an additional 3,057 shares during the period. PDT Partners LLC's holdings in Regeneron Pharmaceuticals were worth $4,315,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Dodge & Cox increased its stake in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock worth $1,653,543,000 after purchasing an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after purchasing an additional 149,124 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on REGN shares. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $892.60.

Regeneron Pharmaceuticals Trading Up 2.6 %

Shares of Regeneron Pharmaceuticals stock traded up $15.61 during trading on Friday, reaching $605.61. 1,606,415 shares of the company were exchanged, compared to its average volume of 744,231. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The firm has a market capitalization of $66.21 billion, a price-to-earnings ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44. The business has a 50-day moving average price of $628.85 and a 200-day moving average price of $714.29.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the firm earned $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.